Publications
Aging Research and Drug Discovery Meeting (ARDD)
August 26-30, 2024 | Copenhagen, Denmark
Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments
Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress)
June 21-25, 2024 | Washington, D.C.
Improvement of Motor and Non-Motor Symptoms with bezisterim (NE3107) Adjunctive to carbidopa/levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study
Assessment of bezisterim (NE3107) in Patients with Early Parkinson’s Disease: A Phase 2, Placebo-Controlled, Hybrid Decentrallized Study
XXIX World Congress on Parkinson’s Disease and Related Disorders hosted by the International Association of Parkinsonism and Related Disorders (IAPRD)
May 19-22, 2024 | Lisbon, Portugal
Improvement of Motor and Non-Motor Symptoms with Bezisterim Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study
12th Annual Alzheimer's & Parkinson's Drug Development Summit
April 23-25, 2024 | Boston, Massachusetts
Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of Bezisterim in Subjects with Mild to Moderate Probable Alzheimer’s Disease
Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of Bezisterim in Subjects with Mild to Moderate Probable Alzheimer’s Disease
International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2024)
March 5-9, 2024 | Lisbon, Portugal
Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s Disease
Improvements of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2a, Placebo-Controlled Study
American Association for the Study of Liver Disease (AASLD)
November 10-14, 2023 | Boston, MA
Safety and Tolerability of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study
Clinical Trials on Alzheimer's Disease conference (CTAD)
October 24 – 27, 2023 | Boston, MA
Oral Presentation: Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer’s Disease
American Neurological Association Annual Meeting
September 11-13, 2023 | Philadelphia, PA
Metabolic Dysregulation in Probable Alzheimer’s Disease
International Congress of Parkinson’s Disease and Movement Disorders
August 27-31, 2023 | Copenhagen, Denmark
Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s Disease in a Marmoset Monkey Model
Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s Disease in a Marmoset Monkey Model
Safety and Pharmacokinetics of Anti-Inflammatory NE3107 Treatment in Carbidopa/Levodopa-TreatedPatients With Parkinson’s Disease: A Phase 2a, Double-Blind, Placebo-Controlled Study
A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial With NE3107 Adjunctive to Carbidopa/Levodopa in Patients With Parkinson’s Disease
Alzheimer’s Association International Conference
July 16-20, 2023 | Amsterdam, Netherlands
Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer’s Disease
83rd Scientific Sessions of the American Diabetes Association
June 23-26, 2023 | San Diego, CA
Metabolic Dysregulation in Probable Alzheimer’s Disease
Metabolic Dysregultion in Probable Alzheimer’s Disease
The International Liver Congress (EASL)
June 21-24 | Vienna, Austria
Safety and Efficacy of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study
2023 World Congress on Parkison’s Disease and Related Disorders (IAPRD)
May 13-16, 2023 | Chicago, IL
Rationale for a Potentially Pivotal Study of NE3107 in Parkinson’s Disease
78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP)
April 27-29, 2023 | San Diego, CA
Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias
Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias
2023 American Academy of Neurology (AAN) Annual Meeting
April 22 – 27, 2023 | Boston, MA
Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s Disease
Multi-Modal Correlation Analyses From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline
Due to Degenerative Dementias
Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
2023 International on Alzheimer's and Parkinson's Disease and Related Neurological Disorders (AD / PD) Conference
March 28 – April 2, 2023 | Gothenburg, Sweden
Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients With Parkinson’s Disease: A Phase 2, Double-Blind, Placebo-Controlled Study
Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s Disease
2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 29 – December 2, 2022 | San Francisco, California
Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
